Organon & Co. (NYSE:OGN) Given Consensus Recommendation of “Hold” by Brokerages

Organon & Co. (NYSE:OGN) has earned a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.80.

Several brokerages have recently issued reports on OGN. Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Morgan Stanley dropped their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th.

Organon & Co. Price Performance

Organon & Co. stock opened at $15.46 on Friday. The company’s 50 day simple moving average is $15.36 and its 200-day simple moving average is $17.34. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The company has a market capitalization of $3.98 billion, a price-to-earnings ratio of 3.07, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. As a group, equities research analysts expect that Organon & Co. will post 3.82 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.25%. The ex-dividend date is Monday, February 24th. Organon & Co.’s dividend payout ratio is presently 22.22%.

Institutional Investors Weigh In On Organon & Co.

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Organon & Co. by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock valued at $453,593,000 after buying an additional 218,165 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Organon & Co. by 1.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock worth $147,634,000 after acquiring an additional 136,760 shares in the last quarter. LSV Asset Management increased its holdings in shares of Organon & Co. by 0.4% in the 4th quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock valued at $112,274,000 after acquiring an additional 30,557 shares during the last quarter. Finally, Deprince Race & Zollo Inc. raised its position in shares of Organon & Co. by 7.0% during the 4th quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company’s stock worth $70,561,000 after acquiring an additional 308,267 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.